Beyond pharmaceutical bandaids: universal access to antiretroviral therapy in Canada Authors: Julien Brisson, Nancy Sheehan, Benoit Lemire, Ken Monteith, Pierre-Marie David Published: 2026 In their CMAJ commentary, Dr. Montaner and colleagues called for universal access to antiretroviral therapy (ART), funded through federal–provincial collaboration, as a prerequisite for ending HIV as a public health threat in Canada.1 Their argument rests on the principle of treatment as prevention: sustained access to ART enables people living with HIV to achieve viral suppression, eliminating the risk of sexual HIV transmission and reducing the incidence of HIV at the population level.2 The urgency of this policy imperative has become increasingly impossible to ignore following Gilead Sciences Canada’s decision, effective June 2026, to discontinue copayment assistance programs for 4 antiretroviral coformulations still in clinical use: Genvoya, Stribild, Odefsey, and Complera (MAX Gilead Support Program: personal communication, 2026). Rather than creating a new problem, this decision exposes a longstanding structural weakness in Canada’s HIV response: access to ART depends on fragmented coverage arrangements and discretionary private assistance rather than a universal public guarantee. Despite Canada’s commitment to publicly funded health care, prescription drug coverage remains uneven across provinces and territories. Several jurisdictions, including British Columbia, Alberta, and Saskatchewan, fully cover ART through public drug plans. By contrast, in Quebec and Ontario, where most people in Canada who are living with HIV reside, patients may face substantial out-of-pocket costs. These coverage gaps carry measurable clinical consequences: among people living with HIV in Ontario, type of drug coverage has been independently associated with viral suppression, indicating that those lacking adequate coverage are less likely to achieve undetectable viral loads.3 In this context, manufacturer copayment assistance programs have become an important, although often unacknowledged, mechanism for maintaining treatment access. Yet these programs merely compensate for the absence of comprehensive public drug coverage. Other countries have demonstrated that universal, publicly funded access to ART can be successfully implemented as a cornerstone of national HIV policy.4 The Canadian federal government should work with provinces and territories to ensure that no person living with HIV incurs costs for ART, regardless of residence, income, or insurance status, through a dedicated national HIV drug program or the inclusion of antiretroviral drugs within a broader publicly funded pharmacare framework. Such investments would complement ongoing efforts to expand access to HIV prevention technologies, including pre-exposure prophylaxis (PrEP), and strengthen Canada’s HIV response. Canada’s 2024 Pharmacare Act demonstrates that publicly guaranteed drug coverage is achievable, yet its first phase covers diabetes medications and contraceptives while leaving antiretroviral drugs outside its scope.5 If Canada is serious about achieving its HIV elimination goals, access to antiretroviral drugs must be recognized not as a discretionary benefit, but as a public good.